These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9056053)

  • 1. Onset of the neuromuscular block simulated in an anatomical model.
    Nigrovic V; Banoub A; Diefenbach C; Mellinghoff H; Buzello W
    Br J Clin Pharmacol; 1997 Jan; 43(1):55-63. PubMed ID: 9056053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of the onset of neuromuscular block based on the early oscillations in the arterial plasma concentrations.
    Bissinger U; Nigrovic V
    Eur J Clin Pharmacol; 1997; 52(1):71-5. PubMed ID: 9143871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volume of the effect compartment in simulations of neuromuscular block.
    Nigrovic V; Proost JH; Amann A; Bhatt SB
    Theor Biol Med Model; 2005 Oct; 2():41. PubMed ID: 16202142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simulation of interaction between two non-depolarizing muscle relaxants: generation of an additive or a supra-additive neuromuscular block.
    Nigrovic V; Amann A
    J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):157-79. PubMed ID: 15379383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition between acetylcholine and a nondepolarizing muscle relaxant for binding to the postsynaptic receptors at the motor end plate: simulation of twitch strength and neuromuscular block.
    Nigrovic V; Amann A
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):23-51. PubMed ID: 12800806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the pharmacodynamic parameters in a model for neuromuscular block.
    Nigrovic V; Anton A; Bengez R
    Med Sci Monit; 2004 Dec; 10(12):BR468-76. PubMed ID: 15567978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of the nondepolarizing neuromuscular block in humans: quantitative aspects.
    Nigrovic V; Banoub M
    Anesth Analg; 1993 Jan; 76(1):85-91. PubMed ID: 8418747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onset-potency relationship of nondepolarizing muscle relaxants: a reexamination using simulations.
    Bhatt SB; Amann A; Nigrovic V
    Can J Physiol Pharmacol; 2007 Aug; 85(8):774-82. PubMed ID: 17901887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved neuromuscular blockade using a novel neuromuscular blockade advisory system: a randomized, controlled, clinical trial.
    Gilhuly TJ; Macleod BA; Dumont GA; Bouzane AM; Schwarz SK
    Anesth Analg; 2008 Nov; 107(5):1609-17. PubMed ID: 18931219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor.
    Jonsson Fagerlund M; Dabrowski M; Eriksson LI
    Anesthesiology; 2009 Jun; 110(6):1244-52. PubMed ID: 19417616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship.
    Pühringer FK; Gordon M; Demeyer I; Sparr HJ; Ingimarsson J; Klarin B; van Duijnhoven W; Heeringa M
    Br J Anaesth; 2010 Nov; 105(5):610-9. PubMed ID: 20876699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugammadex, the first selective relaxant binding agent for neuromuscular block reversal.
    Stair C; Fernandez-Bustamante A
    Drugs Today (Barc); 2012 Jun; 48(6):405-13. PubMed ID: 22745926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacokinetic-pharmacodynamic model for a muscle relaxant: atracurium.
    Nigrovic V; Gaspari J; Banoub M
    Eur J Clin Pharmacol; 1996; 49(4):325-32. PubMed ID: 8857080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of rapacuronium bromide.
    Wight WJ; Wright PM
    Clin Pharmacokinet; 2002; 41(13):1059-76. PubMed ID: 12403643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation of the reversal of neuromuscular block by sequestration of the free molecules of the muscle relaxant.
    Nigrovic V; Bhatt SB; Amann A
    J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):771-88. PubMed ID: 17882536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulation of the kinetics of neuromuscular block: implications for speed of onset.
    Dilger JP
    Anesth Analg; 2013 Oct; 117(4):792-802. PubMed ID: 23456666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle relaxants: a clinical update.
    Buzello W; Diefenbach C; Nigrovic V
    Acta Anaesthesiol Scand Suppl; 1996; 109():165-7. PubMed ID: 8901994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.
    Haerter F; Simons JC; Foerster U; Moreno Duarte I; Diaz-Gil D; Ganapati S; Eikermann-Haerter K; Ayata C; Zhang B; Blobner M; Isaacs L; Eikermann M
    Anesthesiology; 2015 Dec; 123(6):1337-49. PubMed ID: 26418697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer neuromuscular blocking agents: how do they compare with established agents?
    Sparr HJ; Beaufort TM; Fuchs-Buder T
    Drugs; 2001; 61(7):919-42. PubMed ID: 11434449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic modeling of muscle relaxants: effect of design issues on results.
    Paul M; Fisher DM
    Anesthesiology; 2002 Mar; 96(3):711-7. PubMed ID: 11873049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.